HeraldLoop
← Volver a las noticias
2 fuentesSeguimiento desde 21 sept, 15:05

<a href="https://www.fiercebiotech.com/pharma/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions" hreflang="en">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>

CompartirXWhatsAppFacebookLinkedIn

Cobertura cronológica

  1. 21 de septiembre
  2. Más reciente21 sept, 15:23

    <a href="https://www.fiercepharma.com/pharma/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions" hreflang="en">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>

    With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”

    Fierce PharmaFierce Pharma•James Waldron, Fraiser Kansteiner
  3. Primera noticia21 sept, 15:05

    <a href="https://www.fiercebiotech.com/pharma/novo-aims-appease-investors-direct-consumer-plans-blockbuster-ambitions" hreflang="en">Novo struggles to appease restive investors with consumer plans, blockbuster ambitions</a>

    With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a bright future for Novo.”

    Fierce BiotechFierce Biotech•James Waldron, Fraiser Kansteiner